Contents hide 1 Melanoma 2 Non-Small Cell Lung Cancer 3 Dosage Modifications 3.1 Recommended dose reductions for binimetinib for adverse reactions 3.2 Cardiomyopathy 3.2.1 Resume at a reduced dose if the following are present 3.3 Venous thromboembolism 3.3.1 Uncomplicated DVT or PE 3.4 Serous retinopathy 3.4.1 Withhold drug for up to 10 days 3.5 Retinal vein occlusion 3.6 Uveitis 3.6.1 Grades 1-3 3.7 Interstitial lung disease 3.7.1 Grade 2 3.8 Hepatotoxicity 3.8.1 Grade 2 AST/ALT increased 3.8.2 Recurrent Grade 2 or first occurrence of any Grade 3 AST/ALT increased 3.8.3 First occurrence of any Grade 4 AST/ALT increased 3.8.4 Recurrent … Continue reading MEKTODK (Binimetinib)